Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaxcyte Inc (PCVX)

Vaxcyte Inc (PCVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,383,339
  • Shares Outstanding, K 143,920
  • Annual Sales, $ 0 K
  • Annual Income, $ -766,630 K
  • EBIT $ -924 M
  • EBITDA $ -913 M
  • 60-Month Beta 1.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.93

Options Overview Details

View History
  • Implied Volatility 68.66% (+12.28%)
  • Historical Volatility 45.65%
  • IV Percentile 49%
  • IV Rank 35.00%
  • IV High 111.68% on 03/27/25
  • IV Low 45.50% on 01/16/26
  • Expected Move (DTE 14) 5.74 (9.68%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 1,062
  • Volume Avg (30-Day) 658
  • Put/Call OI Ratio 2.48
  • Today's Open Interest 16,285
  • Open Int (30-Day) 10,855
  • Expected Range 53.52 to 65.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.86
  • Number of Estimates 2
  • High Estimate -1.75
  • Low Estimate -1.96
  • Prior Year -1.04
  • Growth Rate Est. (year over year) -78.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.34 +15.49%
on 02/11/26
65.00 -8.78%
on 02/25/26
+3.14 (+5.59%)
since 02/06/26
3-Month
42.40 +39.83%
on 12/18/25
65.00 -8.78%
on 02/25/26
+12.81 (+27.56%)
since 12/05/25
52-Week
27.66 +114.35%
on 04/10/25
76.61 -22.61%
on 03/21/25
-15.52 (-20.75%)
since 03/06/25

Most Recent Stories

More News
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.

For growth-focused biotech investors, Vaxcyte is no longer just a science story.

PCVX : 59.29 (+1.79%)
STRO : 25.29 (+12.40%)
LZAGY : 66.3500 (+0.96%)
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety,...

PCVX : 59.29 (+1.79%)
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027  OPUS-1,...

PCVX : 59.29 (+1.79%)
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter...

PCVX : 59.29 (+1.79%)
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside...

PCVX : 59.29 (+1.79%)
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public...

PCVX : 59.29 (+1.79%)
Vaxcyte Announces Pricing of $550 Million Public Offering

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common...

PCVX : 59.29 (+1.79%)
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering...

PCVX : 59.29 (+1.79%)
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study...

PCVX : 59.29 (+1.79%)
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration  Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head...

PCVX : 59.29 (+1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.

See More

Key Turning Points

3rd Resistance Point 62.56
2nd Resistance Point 61.14
1st Resistance Point 59.70
Last Price 59.29
1st Support Level 56.84
2nd Support Level 55.42
3rd Support Level 53.98

See More

52-Week High 76.61
Last Price 59.29
Fibonacci 61.8% 57.91
Fibonacci 50% 52.14
Fibonacci 38.2% 46.36
52-Week Low 27.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar